Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (ZOMAXEPT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02018172
Recruitment Status :
(Terminated due to lack of recruitment and difficulty in the selection of sites)
The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with a growth hormone deficiency or Turner's syndrome.
Patient with growth hormone deficiency,
Diagnosis of growth hormone deficiency proven by appropriate exploration
Size ≤ -2 Standard Deviation (SD) according to the French references
Growth velocity in the previous year inferior to the normal for age (-1SD) or < 4cm/year
Growth deficiency due to Turner's syndrome
Turner's syndrome confirmed by a karyotype
Patient's size ≤ -2 SD according to the French references
Bone age < 12 years
Patient who require a minimum of 18 months of treatment.
There are no exclusion criteria except the contraindication for Zomacton® 10 mg
Disorders of Sex Development
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Sex Chromosome Disorders
Genetic Diseases, Inborn
Endocrine System Diseases